#SNO2024 poster -A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of LP-184 alone and in combination with Spironolactone in IDH wild type Glioblastoma at First Progression (Abstract Code:CTNI-29)- is now available on our website! Last week, we were excited to attend and present at the #SNO2024 Annual Meeting. Our senior research scientist Aditya Kulkarni, PhD., shared some of the innovative work in collaboration with Johns Hopkins Medicine and were able to connect with the #CancerResearch community. Check out the full poster at our website to learn more: https://bit.ly/3Him1Wm
Lantern Pharma Inc. (Nasdaq: LTRN)
生物技术研究
Dallas，TX 4,550 位关注者
Leveraging Artificial Intelligence to Rescue and Develop Cancer Therapies
关于我们
Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR platform helps to provide rapid, meaningful insight to both of these central problems in oncology. Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.
- 网站
-
https://www.lanternpharma.com
Lantern Pharma Inc. (Nasdaq: LTRN)的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Dallas，TX
- 类型
- 上市公司
- 创立
- 2013
- 领域
- Biotechnology、Cancer Drug Development、Precision Medicine、Biomarkers, Genetic Screen, Companion Diagnostics、PrecisionOncology、Artificial Intelligence、Patient Stratification、Drug Rescue和Drug Repurposing
地点
Lantern Pharma Inc. (Nasdaq: LTRN)员工
-
Jon Coriell, MBA
Senior Executive Leader - Finance
-
Rick Fontenot
Data Scientist
-
Sandra Sinclair, BSBA, MHA/ED, RN
Executive Director, Clinical Operations
-
Aruna Reddy
Bioanalytical Scientist, Quality Assurance Auditor (GCP/GLP/GCLP/ In-vitro Studies/ Nasogastric Studies/ Medical Devices), Clinical Research, Medical…
动态
-
Today, November 22nd, at 7:30PM Central time, Lantern Pharma Inc. (Nasdaq: LTRN) is presenting at the 2024 Society for Neuro-Oncology (SNO) annual meeting. Our senior research scientist Aditya Kulkarni, PhD will be presenting with Karisa Schreck, MD, PhD of Johns Hopkins Medicine. Stay tuned for the poster presentation- "A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of LP-184 alone and in combination with Spironolactone in IDH wild type #Glioblastoma at First Progression (Abstract Code:CTNI-29)" Learn more about the #SNO2024 meeting :https://lnkd.in/ejbVQkgu Visit our website: www.lanternpharma.com
-
-
Lantern Pharma Inc. (Nasdaq: LTRN) announced that the first patient has been dosed in Japan for the Phase 2?HARMONIC? clinical trial?for LP-300 in never-smoker patients with non-small cell lung cancer #NSCLC. This marks a significant expansion of the Harmonic? trial into Asia. But why Asia? ??Non-small cell lung cancer (NSCLC) in never smokers occurs at rates 2 to 3 times higher in East Asian countries versus the US and Europe. ??2 in 5 of all lung cancer patients in East Asia are never smokers ??More than 50% of lung cancer patients in Taiwan and more than 32% in Japan are never smokers. Check out the full press release to learn more about our significant milestone with the expansion of the HARMONIC? trial into Asia! Read the full release: https://bit.ly/3UVasv5 Learn more about the trial: harmonictrial.com Clinicaltrial.gov (NCT05456256): https://lnkd.in/eKHWFphD
-
??Exciting news - ?Lantern Pharma Inc. (Nasdaq: LTRN) announced that the first patient has been dosed in Japan for the Phase 2?HARMONIC? clinical trial?for LP-300 in never-smoker patients with non-small cell lung cancer(#NSCLC). ??Non-small cell lung cancer (NSCLC) in never smokers occurs at rates 2 to 3 times higher in East Asian countries versus the US and Europe. ??Ten clinical trial sites across Japan and Taiwan are actively screening patients, with additional sites expected to also begin patient enrollment in the coming months. ??U.S. clinical sites continue to actively screen and dose patients in both the LP-300 combination arm and the standard-of-care control arm of the Harmonic? trial. This marks an important milestone, driving the next phase of enrollment of the Harmonic trial? - We’re encouraged by the strong support from clinical partners across Asia in advancing this unique trial to improve survival outcomes for never-smokers with lung cancer who have relapsed from TKI-based treatments! Read the full release: https://bit.ly/3UVasv5 Learn more about the trial: harmonictrial.com Clinicaltrial.gov (NCT05456256): https://lnkd.in/eKHWFphD
-
-
Starlight Therapeutics Announced Inaugural Members of Scientific Advisory Board! Stay tuned as Starlight harness the expertise of this esteemed board to drive innovation in CNS and Brain Cancer treatment. Check out the post to learn more:
We are thrilled to announce?Inaugural Members of Scientific Advisory Board of Starlight Therapeutics, marking a major milestone in our commitment to advancing therapies for brain and CNS cancers. We’re honored to be joined by four extraordinary leaders in neuro-oncology: ??Dr. Mitchel S. Berger, M.D. : Chair of the UCSF Department of Neurological Surgery, director of the Brain Tumor Center, Director of Center for Neurological Injury and Repair and, co-director of Adult Brain Tumor Surgery Program at University of California, San Francisco . ??Dr. Lisa M. DeAngelis, M.D. : Chief Physician Executive and Scott M. and Lisa G. Stuart Chair at Memorial Sloan Kettering Cancer Center -oversees all clinical services, research, medical education, and multi-center collaborations, including the 500-bed Memorial Hospital, 13 outpatient facilities, and seven regional care sites across NY and NJ. ??Dr. Stuart Grossman, M.D. : Professor of Oncology at the Johns Hopkins Kimmel Cancer Center, is co-Leader of the Brain Cancer Program and has directed the clinical and research neuro-oncology efforts at Johns Hopkins Medicine since 1981. ??Dr. John Laterra, MD, Ph.D. : is a Professor of Neurology, Oncology and Neuroscience and Co-Director of the Brain Cancer Disease Group at the Johns Hopkins Kimmel Cancer Center. We look forward to the impactful insights they’ll bring to shape the future of our lead candidate, STAR-001. A special congratulations to Drs. Berger and Grossman on receiving the prestigious Lifetime Achievement Award from the Society for Neuro-Oncology Stay tuned as we harness the expertise of this esteemed board to drive innovation in cancer treatment. Read the full PR : https://bit.ly/3YBUHKw Learn more about Starlight Therapeutics: starlightthera.com
-
??In case you missed it - Lantern Pharma Third?Quarter 2024 Operating & Financial Results Conference Call / Webinar is now available on Lantern Pharma Inc. (Nasdaq: LTRN)'s #Youtube Channel! https://lnkd.in/e68eitqR During the call, our CEO and President Panna Sharma and our management shared exciting updates of the quarter. Follow us to join in exploring the forefront of cancer research and treatment! #Earningscall #Q32024
-
Join us TODAY- November 7th, Thursday, 4:30PM Eastern Time for Lantern Pharma Inc. (Nasdaq: LTRN)'s Q3 financial & operating results call. https://bit.ly/40zj91S https://bit.ly/40zj91S Register now to join us as we share our Company’s updates and discuss future milestones ??
-
-
??? #SaveTheDate - November 7th, Thursday, 4:30PM Eastern Time for Lantern Pharma Inc. (Nasdaq: LTRN)'s Q3 financial & operating results call. https://bit.ly/40zj91S https://bit.ly/40zj91S Register now to join us as we share our Company’s updates and discuss future milestones ??
-
-
??In case you missed it -Lantern Pharma Webinar Wednesday: Actuate Therapeutics, Inc. & Lantern Pharma Inc. (Nasdaq: LTRN)'s AI Collaboration - Using Lantern’s?#AI Platform to Accelerate & Advance The Development of a Novel Cancer Drug - The Elragulisib Story is now available on our #Youtube Channel! https://lnkd.in/eS9Qi5M4 Thank you everyone for joining?this month’s Lantern Pharma Webinar Wednesday!?We look forward to your continued excitement and engagement in upcoming #WebinarWednesdays- happening every month, on the last Wednesday of each month. Here are some highlights of the webinar: ???Actuate x Lantern AI Collaboration - the Elraglusib Story ??Andrew discussed about Actuate Therapeutics’ lead drug, Elraglusib, that shows promise in treating advanced cancers ??Andrew and Joseph discussed our collaboration for Better Patient Outcomes - how we are leveraging RADR? AI platform to identify which patients might respond best, aiming to treat with more precision. ?? Andrew also shared Actuate's plans to further advance Elraglusib to multiple cancers. Watch the webinar here: https://lnkd.in/eS9Qi5M4 Follow us to join in exploring the forefront of cancer research and treatment by accessing these insightful webinars for free!
-
-
?? Happening TODAY! -Register now for Lantern Pharma Webinar Wednesday: Actuate Therapeutics, Inc. &Lantern Pharma Inc. (Nasdaq: LTRN) 's AI Collaboration - Using Lantern’s #AI Platform to Accelerate & Advance The Development of a Novel Cancer Drug - The Elraglusib Story. https://bit.ly/3YmYxIq https://bit.ly/3YmYxIq